Business Wire

CA-GREEN-STREET

30.1.2024 09:08:27 CET | Business Wire | Press release

Share
Green Street Releases 2024 Pan-European Sector Outlooks with Market Forecasts

Green Street, the preeminent provider of actionable commercial real estate intelligence and analytics, has released its 2024 Pan-European Sector Outlooks, a bundle of in-depth research reports covering commercial real estate. The Outlook reports provide a 360-degree view of the four core property sectors and can be utilized in conjunction with our Market Forecasts tool, which provides five-year forecasts for operating fundamentals and valuation metrics across various scenarios for the top 30 Pan-European markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130899540/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New Insights! Green Street's 2024 Sector Outlooks and Expanded Market Reports Are Here. Explore Sector Dynamics, Market Fundamentals and Valuation Trends. (Graphic: Business Wire)

The 2024 Pan-European Industrial, Office, Residential and Retail Sector Outlooks include supply/demand analysis, growth forecasts, valuation metrics, and NUTS3 and Market Grades representing long-term growth potential.

“Industrial and retail remain Green Street’s preferred sectors from a long-term hold perspective. Strength of the demand has been fueling industrial rental growth, whilst high incoming yield in retail bolster returns,” explains Marie Dormeuil, Head of European Market Analytics. “On the other hand, office remains a laggard for the fourth consecutive year. The observed yield expansion is not enough to offset the drag in fundamentals entailed by the bifurcation in tenants’ demand in favour of prime offices.”

Below are key takeaways from each sector:

  • Industrial: Opportunities Plentiful

M-RevPAM growth – a Green Street proprietary metric that combines effective market rent and occupancy – is forecast to exhibit a more level-playing field than history has played out, and whilst there is a wide dispersion between key European cities, growth is positive across the board. There are signals that values have bottomed and yields are showing tentative signs of tightening. Institutional investors who have been hopeful for a lower price point and/or sought greater assurance on the operating backdrop now have their potential opportunity.

  • Retail: Firmer Footings

Europe's downbeat consumer has kept spending despite the uncertain outlook. The pressure on consumer discretionary spend which has been well documented in news headlines has not (yet) necessarily translated into weakening tenant sales. Retailer occupational fundamentals are surprisingly sturdy and, moreover, given the value destruction experienced in the pandemic, several green shoots are emerging in terms of rental growth. Combined with the high initial yields on offer, potential unlevered returns are alluring for centres that are dominant in their catchment. According to Green Street’s Multichannel Desirability Index, which ranks markets in order of where a retailer (and landlord) is most likely to flourish, U.K. cities screen amongst the most favourable places for both ecommerce and physical retailers.

  • Office: Crystal Ball Gazing

Key risks to the office sector include a softer macro-outlook (redundancies) and improved productivity due to remote working. The bifurcation in favour of 'A' space that began to assert itself post-pandemic accelerated in '23, eroding further fundamentals for 'B'-quality. Flight to quality by tenants should accelerate operational obsolescence of some of Europe’s more secondary office stock, leading to demolition or conversion to other uses. Developers are likely to find better risk-adjusted (i.e., lower environmental impact, lower development risk) returns on offer by pursuing major refurbishment and/or redevelopment works relative to ground-up new construction projects.

  • Residential: More Cheery Than Gloomy

The positive long-term structural trends of solid demand (household formation and immigration) and lack of supply outweigh the headwinds facing the European residential sector. Meanwhile, the outlook for new residential construction is muted as the rise in interest rates has derailed development economics. Pan-European residential asset prices are down ~24% from mid-'22 peak and a bottom might be forming; signals from the fixed income and public equity markets are pointing to moderate upside to private market valuations for the first time after 18 months. Governments' appetite for rent controls and stretched affordability are near-term risks to watch out for.

Request a sample report for more information on Green Street’s Sector Outlooks.
Register now to join the upcoming Pan-European Private Markets Webinar.
To learn more about Green Street’s Market Forecasts Tool, click here.

About Green Street

Green Street is the preeminent provider of actionable commercial real estate research, news, data, analytics, and advisory services in the U.S. and Europe. For more than 35 years, Green Street has delivered unparalleled intelligence and trusted data on the public and private real estate markets, helping investors, banks, lenders, and other industry participants optimize investment and strategic decisions. The firm delivers exclusive market information, conclusion-driven insights, and predictive analytics through a SaaS platform.

Green Street's US Research, Data, and Analytics products along with its global news publications are not provided as an investment advisor nor in the capacity of a fiduciary.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130899540/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye